Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
GSK’s Phase I/II herpes simplex vaccine trial misses primary endpoint
GSK has announced that Part II of the Phase I/II TH HSV REC-003 trial of its therapeutic herpes simplex virus (HSV) vaccine candidate, GSK3943104, did not meet its primary efficacy endpoint. The results were evidenced in an analysis of primary objective data from the Phase II part of the trial.
GSK Abandons Herpes Vaccine After Disappointing Phase I/II Proof-of-Concept Data
Without revealing specific details, GSK announced that it is terminating the development of its investigational herpes simplex virus vaccine after failing to meet the study’s primary efficacy objective.
GSK’s Herpes Shot Fails in Early Trial in Blow for Drugmaker
GSK Plc’s experimental vaccine for herpes failed in an early-stage trial, halting an effort to bring the first shot for the condition to market.
Pharmalittle: We’re reading about a Novo weight loss study, a GSK vaccine failure, and more
Hello, everyone, and how are you today? We are doing just fine, thank you, especially since the middle of the week is upon us. After all, we have made it
GSK Ends Development of Herpes Vaccine Candidate After Disappointing Trial Results
A study investigating GSK’s investigational herpes simplex virus (HSV) vaccine candidate failed to meet its primary efficacy endpoint.
GSK's experimental herpes vaccine fails to meet main goal in trial
(Reuters) -British drugmaker GSK said on Wednesday its experimental herpes simplex virus (HSV) vaccine candidate failed to meet the main goal of a mid-stage trial and would not be taken forward to a late-stage trial.
GSK's HSV Vaccine Study Fails to Meet Primary Efficacy Goal
GSK plc GSK announced that its therapeutic herpes simplex virus (HSV) vaccine candidate, GSK3943104, did not meet the primary endpoint in the combined phase I/II proof-of-concept study. The phase I/II TH HSV REC-003 study evaluated the clinical efficacy of the early-stage HSV vaccine candidate GSK3943104.
15h
on MSN
People are protecting through this rally and we might retrace lower: Simplex Trading's Jason Coogan
Jason Coogan, Simplex Trading, joins 'Power Lunch' to discuss Coogan's complex given the notion that stocks have soared, what ...
1d
GSK's Respiratory Syncytial Virus Vaccine Given Together With Shingles Shot Shows Non-Inferior Immune Response In Older Adults
GSK released data from a Phase 3 trial evaluating the co-administration of Arexvy and Shingrix vaccines in adults 50+. The ...
FierceBiotech
9d
GSK surrenders HSV vaccine hopes after phase 2 fail, ceding race to Moderna, BioNTech
GSK’s attempt to develop the first vaccine for herpes simplex virus (HSV) has ended in failure, leaving the race open for the ...
Rolling Out
5d
4 reasons to prevent a fever blister from returning
While they can heal naturally, preventing a fever blister from recurring should be a priority for anyone who has experienced ...
8d
GSK Halts Herpes Simplex Virus Vaccine Development, Clears Path For Other Contenders Like Moderna, BioNTech
GSK Plc has halted development of its herpes simplex virus vaccine, GSK3943104, after it failed to meet efficacy goals in ...
Yahoo
3d
Is Eczema an Autoimmune Disease or Something Else?
Neurodermatitis (lichen
simplex
chronicus) causes itchy skin that can become thickened and discolored over time. Nummular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback